Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 3
Submit an article Journal homepage
195
Views
15
CrossRef citations to date
0
Altmetric
Review

Intracellular immune dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: state of the art and therapeutic implications

Jo Nijs Assistant professor Vrije Universiteit Brussel, Faculty of Physical Education & Physiotherapy, Department of Human Physiology, Building L, Pleinlaan 2, 1050 Brussels, Belgium +32 2 629 2222; +32 2 477 4607; [email protected]; University College Antwerp, Division of Musculoskeletal Physiotherapy, Department of Health Care Sciences, Belgium
, PhD &
Marc Frémont RED Laboratories N.V., Zellik, Belgium
, PhD
Pages 281-289 | Published online: 13 Feb 2008

Bibliography

  • Gerrity TR, Papanicolaou DA, Amsterdam JD, et al. Immunologic aspects of chronic fatigue syndrome. Neuroimmunomodulation 2004;11:351-7
  • Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol 2002;9:747-52
  • Van Middendorp H, Geenen R, Kuis W, et al. Psychological adjustment of adolescent girls with chronic fatigue syndrome. Pediatrics 2001;107:1-8
  • Demitrack MA. Chronic fatigue syndrome and fibromyalgia: dilemmas in diagnosis and clinical management. Psych Clin North Am 1998;21:671-92
  • Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998;78:55-113
  • Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003;42:1805-12
  • Nijs J, De Meirleir K. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. In Vivo 2005;9:1013-22
  • Malathi K, Dong B, Gale M Jr, Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007;448:816-20
  • Iordanov MS, Wong J, Bell JC, Magun BE. Activation of NF-κB by double-stranded RNA (dsRNA) in the absence of protein kinase R and RNase L demonstrates the existence of two separate dsRNA-triggered antiviral programs. Mol Cell Biol 2001;21:61-72
  • De Meirleir K, Bisbal C, Campine I, et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for Chronic Fatigue Syndrome. Am J Med 2000;108:99-105
  • Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18:S96-104
  • Suhadolnik RJ, Peterson DL, Cheney PR, et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndr 1999;5:223-42
  • Frémont M, El Bakkouri K, Vaeyens F, et al. 2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. Exp Mol Path 2005;78:239-46
  • Demettre E, Bastide L, D'Haese A, et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of Chronic Fatigue Syndrome patients. J Biol Chem 2002;277:35746-51
  • Englebienne P, Herst CV, De Smet K, D'Haese A, De Meirleir K. Interactions between RNase L ankyrin-like domain and ABC transporters as a possible origin for pain, ion transport, CNS and immune disorders of chronic fatigue immune dysfunction syndrome. J Chronic Fatigue Syndr 2001;8:83-9
  • Meeus M, Nijs J, McGregor N, et al. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage, and elastase activity and their clinical relevance. In Vivo 2008:In Press
  • Shetzline SE, Martinand-Mari C, Reichenbach NL, et al. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 2002;22:443-56
  • Tiev KP, Briant M, Ziani M, et al. Variability of the RNase L isoform ratio (37 kilodaltons/83 kilodaltons) in diagnosis of chronic fatigue syndrome. Clin Diagn Lab Immunol 2005;12:366
  • Frémont M, Vaeyens F, Herst CV, et al. 37-kilodalton/83-kilodalton RNase L isoform ratio in peripheral blood mononuclear cells: analytical performance and relevance for chronic fatigue syndrome. Clin Diagn Lab Immunol 2005;12:1259-60
  • Kumar S, Mitnik C, Valente G, et al. Expansion and molecular evolution of the interferon-induced 2′-5′ oligoadenylate synthetase gene family. Mol Biol Evol 2000;17:738-50
  • Marie I, Blanco J, Rebouillat D, et al. 69-kDa and 100-kDa isoforms of interferon-induced (2′-5′) oligoadenylate synthetase exhibit differential catalytic parameters. Eur J Biochem 1997;248:558-66
  • Hartmann R, Norby PL, Martensen PM, et al. Activation of 2′-5′ oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers. J Biol Chem 1998;273:3236-46
  • Sarkar SN, Bandyopadhyay S, Ghosh A, et al. Enzymatic characteristics of recombinant medium isozyme of 2′-5′ oligoadenylate synthetase. J Biol Chem 1999;274:1848-55
  • Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of Gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007;99(1-3):237-40
  • Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in Chronic Fatigue Syndrome. J Interferon Cytokine Res 1997;17:377-85
  • Suhadolnik RJ, Reichenbach NL, Hitzdes P, et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 1994;8:599-604
  • Ikuta K, Yamada T, Shimomura T, et al. Diagnostic evaluation of 2′,5′-oligoadenylate synthetase activities and antibodies against Epstein-Barr virus and Coxiella burnetti in patients with chronic fatigue syndrome in Japan. Microbes Infect 2003;5:1096-102
  • Vojdani A, Choppa PC, Lapp CW. Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome. J Clin Lab Immunol 1998;50:1-16
  • Gow JW, Simpson K, Behan PO, et al. Antiviral pathway in patients with chronic fatigue syndrome and acute infection. Clin Infect Dis 2001;32:2080-1
  • Shetzline SE, Suhadolnik RJ. Additions and corrections – characterization of a 2′,5′-oligoadenylate (2-5A)-dependent 37-kDa RNase L. Azido photoaffinity labeling and 2-5A-dependent activation. J Biol Chem 2001;276:23707-11
  • Kennedy G, Spence V, Underwood C, Belch JJF. Increased neutrophil apoptosis in chronic fatigue syndrome. J Clin Pathol 2004;57:891-3
  • Frémont M, D'Haese A, Roelens S, et al. Immune celle apoptosis and chronic fatigue syndrome. Chapter 6. In: Chronic Fatigue Syndrome. A Biological Approach. Englebienne P, De Meirleir K, editors, Boca Raton: CRC Press; 2002. p. 131-74
  • Englebienne P. RNase L in health and disease-What did we learn recently? J Chronic Fatigue Syndr 2003;11:97-109
  • Roelens S, Herst CV, D'Haese A, et al. G-actin cleavage parallels 2-5A-dependent RNase L cleavage in peripheral blood mononuclear cells – relevance to a possible serum-based screening test for dysregulations in the 2-5A pathway. J Chronic Fatigue Syndr 2001;8:63-82
  • Frémont M, Vaeyens F, Herst CV, et al. Antiviral pathway deregulation of chronic fatigue syndrome induces nitric oxide production in immune cells that precludes a resolution of the inflammatory response. J Chronic Fatigue Syndr 2006;13:17-28
  • Nijs J, Meeus M, De Meirleir K, et al. Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response. Med Hypotheses 2004;62:759-65
  • Maes M, Mihaylova I, Bosmans F. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett 2007;28:456-62
  • Maes M, Mihaylova I, Kubera M, Bosmans F. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:463-9
  • Paludan SR, Ellermann-Eriksen S, Mogensen SC. NF-κB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-γ-induced nitric oxide production in macrophages. J Gen Virol 1998;79:2785-93
  • Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosci 2003;113:683-701
  • Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypothesis 2001;57(2):139-45
  • Siegel SD, Antoni MH, Fletcher MA, et al. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup? J Psychosom Res 2006;60:559-66
  • Nijs J, Demanet C, McGregor NR, et al. Monitoring a hypothetical channelopathy in chronic fatigue syndrome: preliminary observations. J Chronic Fatigue Syndr 2003;11:117-33
  • Nijs J, De Meirleir K, Coomans D, et al. Deregulation of the 2,5A synthetase RNase L antiviral pathway by Mycoplasma spp. in subsets of chronic fatigue syndrome. J Chronic Fatigue Syndr 2003;11:37-50
  • Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006;333:575
  • Vernon SD, Whistler T, Cameron B, et al. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis 2006;6:15
  • Manu P. Chronic fatigue syndrome: the fundamentals still apply. Am J Med 2000;108:172-3
  • Nijs J, De Becker P, De Meirleir K, et al. Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome. Chest 2003;123:998-1007
  • Snell CR, Vanness JM, Strayer DR, Stevens SR. Physical performance and prediction of 2-5A Synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 2002;16:107-10
  • Snell CR, Vanness JM, Strayer DR, Stevens SR. Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS). In Vivo 2005;19:387-90
  • Nijs J, Meeus M, McGregor NR, et al. Chronic fatigue syndrome: exercise performance related to immune dysfunction. Med Sci Sports Exerc 2005;37:1647-54
  • Edmonds M, McGuire H, Price J. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2004;3:CD003200
  • Jammes Y, Steinberg JG, Mambrini O, et al. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005;257:299-310
  • Lapp CW. Exercise limits in chronic fatigue syndrome. Am J Med 1997;103:83-4
  • Bazelmans E, Blijenberg G, Voeten MJM, et al. Impact of a maximal exercise test on symptoms and activity in chronic fatigue syndrome. J Psychosom Res 2005;59:201-8
  • Black CD, O'Conner PJ, McCully KK. Increased daily physical activity and fatigue symptoms in chronic fatigue syndrome. Dynam Med 2005;4:3
  • Knoop H, Bleijenberg G, Gielissen MFM, et al. Is a full recovery possible after cognitive behavioural therapy in chronic fatigue syndrome? Psychother Psychosom 2007;76:171-6
  • Sorensen B, Streib JE, Strand M, et al. Complement activation in a model of chronic fatigue syndrome. J Allergy Clin Immunol 2003;12:397-403
  • Ohashi K, Yamamoto Y, Natelson BH. Activity rhythm degrades after strenuous exercise in chronic fatigue syndrome. Physiol Behav 2002;77:39-44
  • Hawk C, Jason LA, Torres-Harding S. Differential diagnosis of chronic fatigue syndrome and major depressive disorder. Int J Behav Med 2006;13:244-51
  • Whistler T, Jones JF, Unger ER, Vernon SD. Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol 2005;5:5
  • Ushijima H, Rytik PG, Schacke H, et al. Mode of action of the anti-AIDS compound poly(I).poly(CU) (Ampligen): activator of 2′,5′-oligoadenylate synthetase and double-stranded RNA-dependent kinase. J Interferon Res 1993;13(2):161-71
  • Ablashi DV, Berneman ZN, Williams M, et al. Ampligen inhibits human herpesvirus-6 in vitro. In Vivo 1994;8(4):587-91
  • Ueno Y, Okatani S, Yamada Y, et al. Synthesis of double-headed 2-5A-antisense chimeras and their ability to activate human RNase L. Nucleic Acids Res Suppl 2003;3:63-4
  • Kitade Y, Wakana M, Tsuboi T, et al. 2-methyladenosine-substituted 2′,5′-oligoadenylates: conformations, 2-5A binding and catalytic activities with human ribonuclease L. Bioorg Med Chem Lett 2000;10(4):329-31
  • Dessislava ID, Reichenbach N, Yang X, et al. Inhibition of HIV-1 replication in CD4+ and CD14+ cells purified from HIV-1-infected individuals by the 2-5A agonist immunomodulator, 2-5ANB. AIDS Res Hum Retroviruses 2007;23(1):123-34
  • Thakur CS, Jha BK, Dong B, et al. Small molecule activators of RNase L with broad spectrum antiviral activity. Proc Natl Acad Sci USA 2007;104(23):9585-90
  • Shapiro SD. Neutrophil elastase. Path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol 2002;26:266-8
  • Donta ST, Engel CC Jr, Collins JF, et al. Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;14:85-94

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.